Note from the National Guideline Clearinghouse (NGC): The National Institute for Health and Clinical Excellence (NICE) commissioned an independent academic centre to perform a systematic literature review on the technology considered in this appraisal and prepare an Evidence Review Group (ERG) report. The ERG report for this technology appraisal was prepared by the School of Health and Related research (ScHAAR), University of Sheffield. (See the "Availability of Companion Documents" field).
Description of Manufacturer's Search Strategy and Comment on Whether the Search Strategy Was Appropriate
The manufacturers searched ten publicly accessible databases (to December 1, 2006): MEDLINE, EMBASE, Cochrane, AMED, CINAHL, TOXNET, Development and Reproductive Toxicology, Hazardous Substances Databank, Psych-info and Web of Science. They also searched the bibliographies of published systematic reviews and Pfizer's own clinical trials database. Searches were not limited by language, sex or age. A substantial proportion of the clinical effectiveness section of the manufacturer's submission, is based on a separate piece of work, undertaken by researchers at McMaster University, funded by Pfizer, and previously published in a peer-reviewed journal (BMC Public Health).
Manufacturer's Submission: Clinical Evidence Search Strategy
The search utilises a combination of free-text and Medical Subject Headings (MeSH) terms. However it is not clear from the reporting of the search strategy which terms are free-text and which are MeSH. Regarding the MeSH terms, it is not reported whether these were exploded or focused. Similarly it is not reported which fields were searched for the free-text terms (e.g. all fields, title and abstract, title only, etc). Boolean operators are not reported so it is not possible to identify the relationship between the search terms. No methodological search filters have been used and the search utilised terms for the intervention only – no terms for population, outcome or comparator(s) were included in the search. In general, the search methodology is not sufficiently "transparent" to replicate exactly.
Manufacturer's Submission: Cost-Effectiveness Search Strategy
The terms used for the cost-effectiveness search appear to be exactly same as the clinical evidence search; therefore, all the issues surrounding the clinical effectiveness searches also apply to the cost-effectiveness searches. Four databases were searched to identify studies relating to the cost-effectiveness of varenicline. Two of these databases were the same as the clinical evidence search, so presumably the same results were retrieved. Two additional databases that had not been searched for clinical evidence were also searched for cost-effectiveness evidence. One of these was the National Health Service (NHS) Economic Evaluation Database (EED); this was the only database where a different search strategy was applied. The search strategy reported for EED is very basic (searching for the term 'smoking') which at the time of writing would retrieve 355 references. If a more sensitive search strategy was used, including cost-effectiveness terms, fewer references would be retrieved and these would be more specific to the topic.
The McMaster Review
The search strategy for the McMaster review is identical to that of the manufacturer's submission, but it does not specify search terms (presumably it included terms to identify nicotine replacement therapy (NRT) and bupropion trials, as well as trials for varenicline) and there is no sample search strategy as in the manufacturer's submission.
Statement of the Inclusion/Exclusion Criteria Used in the Study Selection and Comment on Whether They Were Appropriate
The Manufacturer's Submission
The manufacturer's evidence review eligibility criteria were any randomised controlled trials (RCT) of at least one year's duration which evaluated NRT (however delivered), bupropion or varenicline using chemical confirmation of smoking cessation, defined as either sustained abstinence or point-prevalence of abstinence. The manufacturer claims to have excluded dose ranging studies, non-RCTs, post-hoc analyses, maintenance therapy, and studies that reported outcomes as self-report were excluded.
The McMaster Review
The McMaster review states the same inclusion criteria as the manufacturer's submission.
What Studies Were Included in the Submission and What Were Excluded
The Manufacturer's Submission
Although the manufacturer's submission states that eligible studies were those evaluating NRT, bupropion or varenicline, they only report, tabulate and discuss studies which evaluate varenicline (regardless of comparator). The Evidence Review Group (ERG) has re-run what they believe might approximate the manufacturer's search strategy and confirms that the table of identified varenicline studies in the manufacturer's submission is complete.
Refer to Section 4.1 of the ERG Report for detailed description of included and excluded studies.